These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 9798077)

  • 21. CYP1A2 activity as measured by a caffeine test predicts clozapine and active metabolite steady-state concentrationin patients with schizophrenia.
    Ozdemir V; Kalow W; Posner P; Collins EJ; Kennedy JL; Tang BK; Albers LJ; Reist C; Roy R; Walkes W; Afra P
    J Clin Psychopharmacol; 2001 Aug; 21(4):398-407. PubMed ID: 11476124
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Plasma clozapine concentration coefficients of variation in a long-term study.
    Diaz FJ; de Leon J; Josiassen RC; Cooper TB; Simpson GM
    Schizophr Res; 2005 Jan; 72(2-3):131-5. PubMed ID: 15560958
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The clinical use of clozapine plasma concentrations in the management of treatment-refractory schizophrenia.
    Miller DD
    Ann Clin Psychiatry; 1996 Jun; 8(2):99-109. PubMed ID: 8807035
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clozapine plasma level monitoring: current status.
    Cooper TB
    Psychiatr Q; 1996; 67(4):297-311. PubMed ID: 8938830
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Influence of dose, cigarette smoking, age, sex, and metabolic activity on plasma clozapine concentrations: a predictive model and nomograms to aid clozapine dose adjustment and to assess compliance in individual patients.
    Rostami-Hodjegan A; Amin AM; Spencer EP; Lennard MS; Tucker GT; Flanagan RJ
    J Clin Psychopharmacol; 2004 Feb; 24(1):70-8. PubMed ID: 14709950
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clozapine and norclozapine concentrations in serum and plasma samples from schizophrenic patients.
    Hermida J; Paz E; Tutor JC
    Ther Drug Monit; 2008 Feb; 30(1):41-5. PubMed ID: 18223461
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Relationship between clinical efficacy and clozapine concentrations in plasma in schizophrenia: effect of smoking.
    Hasegawa M; Gutierrez-Esteinou R; Way L; Meltzer HY
    J Clin Psychopharmacol; 1993 Dec; 13(6):383-90. PubMed ID: 8120151
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clozapine: more than 900 mg/day may be needed.
    Maccall C; Billcliff N; Igbrude W; Natynczuk S; Spencer EP; Flanagan RJ
    J Psychopharmacol; 2009 Mar; 23(2):206-10. PubMed ID: 18515467
    [TBL] [Abstract][Full Text] [Related]  

  • 29. What is an adequate trial with clozapine?: therapeutic drug monitoring and time to response in treatment-refractory schizophrenia.
    Schulte P
    Clin Pharmacokinet; 2003; 42(7):607-18. PubMed ID: 12844323
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Concentrations in plasma clozapine levels in schizophrenic and schizoaffective patients.
    Iglesias García C; Iglesias Alonso A; Bobes J
    Rev Psiquiatr Salud Ment; 2017; 10(4):192-196. PubMed ID: 28844295
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clozapine dose-concentration relationships in plasma, hair and sweat specimens of schizophrenic patients.
    Cirimele V; Kintz P; Gosselin O; Ludes B
    Forensic Sci Int; 2000 Jan; 107(1-3):289-300. PubMed ID: 10689581
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Relationship between clozapine dose, serum concentration, and clinical outcome in children and adolescents in clinical practice.
    Wohkittel C; Gerlach M; Taurines R; Wewetzer C; Unterecker S; Burger R; Schreck D; Mehler-Wex C; Romanos M; Egberts K
    J Neural Transm (Vienna); 2016 Aug; 123(8):1021-31. PubMed ID: 27221285
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Therapeutic drug monitoring-based clozapine dosing recommendations.
    Zernig G; Ng K; Hiemke C; Saria A
    Ther Drug Monit; 2007 Feb; 29(1):130-1. PubMed ID: 17304162
    [No Abstract]   [Full Text] [Related]  

  • 34. Dosing strategies of clozapine-fluvoxamine cotreatment.
    Lu ML; Lane HY; Jann MW; Chang WH
    J Clin Psychopharmacol; 2002 Dec; 22(6):626-8. PubMed ID: 12454566
    [No Abstract]   [Full Text] [Related]  

  • 35. Weight gain during a double-blind multidosage clozapine study.
    de Leon J; Diaz FJ; Josiassen RC; Cooper TB; Simpson GM
    J Clin Psychopharmacol; 2007 Feb; 27(1):22-7. PubMed ID: 17224708
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clozapine and desmethylclozapine: correlation with neutrophils and leucocytes counting in Mexican patients with schizophrenia.
    Vaquero-Baez M; Díaz-Ruíz A; Tristán-López L; Aviña-Cervantes C; Torner C; Ramírez-Bermúdez J; Montes S; Ríos C
    BMC Psychiatry; 2019 Oct; 19(1):295. PubMed ID: 31597566
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Plasma clozapine, norclozapine, and the clozapine:norclozapine ratio in relation to prescribed dose and other factors: data from a therapeutic drug monitoring service, 1993-2007.
    Couchman L; Morgan PE; Spencer EP; Flanagan RJ
    Ther Drug Monit; 2010 Aug; 32(4):438-47. PubMed ID: 20463634
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Response of patients with treatment-refractory schizophrenia to clozapine within three serum level ranges.
    VanderZwaag C; McGee M; McEvoy JP; Freudenreich O; Wilson WH; Cooper TB
    Am J Psychiatry; 1996 Dec; 153(12):1579-84. PubMed ID: 8942454
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of three dosing models for the prediction of steady-state trough clozapine concentrations.
    Paz E; Bouzas L; Hermida J; Brenlla J; Tutor JC
    Clin Biochem; 2008 May; 41(7-8):603-6. PubMed ID: 18280253
    [TBL] [Abstract][Full Text] [Related]  

  • 40. ABCB1 polymorphisms are associated with clozapine plasma levels in psychotic patients.
    Consoli G; Lastella M; Ciapparelli A; Catena Dell'Osso M; Ciofi L; Guidotti E; Danesi R; Dell'Osso L; Del Tacca M; Di Paolo A
    Pharmacogenomics; 2009 Aug; 10(8):1267-76. PubMed ID: 19663671
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.